Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Study of LAROTAXEL + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer

NCT00625664 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00625664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00625664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Study of LAROTAXEL + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
February 29, 2008
Completion date
February 28, 2011
Enrollment
337 (actual)
Sites
160

Conditions

As the registry lists them; a condition with its own page is linked.

urinary bladder neoplasms